Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nutritional epidemiology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Nutritional epidemiology. Displaying page 1 of 1.
    EudraCT Number: 2022-002140-51 Sponsor Protocol Number: INV-CL-106 Start Date*: 2022-12-21
    Sponsor Name:Inversago Pharma Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients with Diabetic Kidney Disease
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004857 10084917 Diabetic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000019-26 Sponsor Protocol Number: D5670C00013 Start Date*: 2018-05-04
    Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca
    Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects with Type 2 Diabetes Mellitus and Renal Impairment
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002181-32 Sponsor Protocol Number: RG012-03 Start Date*: 2016-12-07
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Pat...
    Medical condition: Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003190-26 Sponsor Protocol Number: BUR03 Start Date*: 2020-12-21
    Sponsor Name:Julius-Maximilian University of Würzburg
    Full Title: An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER
    Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FGF...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10077957 X-linked hypophosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003527-14 Sponsor Protocol Number: D9480C00023 Start Date*: 2021-12-17
    Sponsor Name:ASTRAZENECA AB
    Full Title: An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia
    Medical condition: Patients with Chronic Kidney Disease treated for Hyperkalaemia whilst in hospital, who are normokalemic and established on maintenance dose of SZC at discharge.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10020646 Hyperkalaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) FR (Completed) NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003825-41 Sponsor Protocol Number: TRCA-301 Start Date*: 2017-09-21
    Sponsor Name:Tricida, Inc.
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis
    Medical condition: Metabolic acidosis associated with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027417 Metabolic acidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000344-67 Sponsor Protocol Number: DCR-PHXC-104 Start Date*: 2020-08-07
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hype...
    Medical condition: Primary Hyperoxaluria Type 3
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002878-50 Sponsor Protocol Number: NN9535-4321 Start Date*: 2019-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) SK (Completed) BG (Completed) DE (Completed) ES (Ongoing) FR (Completed) PL (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001485-35 Sponsor Protocol Number: LPS17007 Start Date*: 2022-10-03
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naï...
    Medical condition: Type 2 Diabetes Mellitus and Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005326-19 Sponsor Protocol Number: NN9924-4234 Start Date*: 2016-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000324-34 Sponsor Protocol Number: APD356-G000-401 Start Date*: 2014-09-10
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Even...
    Medical condition: Obese and overweight patients with cardiovascular (CV) disease and/or multiple CV risk factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001069-28 Sponsor Protocol Number: D5881C00004 Start Date*: 2015-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
    Medical condition: Severe persistent Hypertriglyceridemia in High Cardiovascular Risk Patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) EE (Completed) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006550-96 Sponsor Protocol Number: TN-07 Start Date*: 2007-03-23
    Sponsor Name:NIDDK TYPE 1 DIABETES TRIALNET
    Full Title: Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus
    Medical condition: prevention of type 1 diabetes mellitus in subjects at risk for T1DM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed) DE (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002249-13 Sponsor Protocol Number: TN-18 Start Date*: 2014-09-11
    Sponsor Name:TrialNet Coordinating Center
    Full Title: CTLA-4Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: A soluble fusion protein, CTLA-4 Ig, is to be used for the prevention of abnormal glucose tolerance and diabetes in relatives at risk of developing the disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) DE (Completed) FI (Completed) IT (Ongoing) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002248-98 Sponsor Protocol Number: TN-10 Start Date*: 2016-01-15
    Sponsor Name:TrialNet Coordinating Center
    Full Title: Anti-CD3 mAb (teplizumab) for prevention of diabetes in relatives at-risk for Type 1 diabetes mellitus
    Medical condition: Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000149-34 Sponsor Protocol Number: CR845-310302 Start Date*: 2023-01-17
    Sponsor Name:Cara Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000828-19 Sponsor Protocol Number: NN9535-4662 Start Date*: 2021-01-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 21:31:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA